Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30202941.
- Also identified by DOI 10.1093/cid/ciy774 and PMC identifier 6376080.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical trials for Staphylococcus aureus bloodstream infections (SAB) are broadly grouped into 2 categories: registrational trials intended to support regulatory approval of antibiotics for the treatment of SAB and strategy trials intended to inform clinicians on the best treatment options for SAB among existing antibiotics. Both types of SAB trials are urgently needed but have been limited by cost, complexity, and regulatory uncertainty. Here, we review key SAB trial design considerations for investigators, sponsors, and regulators.
Medical subject headings
- Anti-Bacterial Agents
- Clinical Trials as Topic
- Research Design
- Sepsis
- Staphylococcal Infections
- Staphylococcus aureus